ASE · Biotechnology

AIM ImmunoTech Inc. (AIM) Stock

$0.18 -1.75% ASE: AIM Healthcare

Valuation

MetricValue
Price$0.18
Market Cap$7.04M
P/E Ratio-0.05
P/B Ratio0.42
P/S Ratio78.36
EPS (TTM)$-8.62
52-Week High$2.79
52-Week Low$0.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE952.76%
ROA-112.09%
ROCE-142.02%
Gross Margin-1.79%
Operating Margin-103.70%
Net Margin-141.23%
Debt/Equity0.51
Current Ratio0.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-20.0M$-32.0M$-20.0M$-11.0M
Net Profit$-19.0M$-19.0M$-29.0M$-17.0M$-14.0M
EPS$-14.67$-14.69$-21.64$-11.22$-8.62
Op Margin-13954.1%-14129.6%-15800.0%-11630.6%-11961.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$40.0M$19.0M$9.0M$6.0M
Total Liabilities$1.0M$2.0M$9.0M$10.0M$16.0M
Cash$32.0M$27.0M$5.0M$2.0M$1.0M
Borrowings$0$1.0M$1.0M$3.0M$5.0M

Latest News

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program GlobeNewswire · Jul 7, 2026 AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones GlobeNewswire · Jun 24, 2026 AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series GlobeNewswire · Jun 22, 2026 AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient MT Newswires · Jun 18, 2026 AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-16.0M$-21.0M$-15.0M$-11.0M
Investing Cash Flow$-1.0M$11.0M$-1.0M$5.0M$1.0M
Financing Cash Flow$0$0$0$3.0M$0
Net Cash Flow$-6.0M$-5.0M$-22.0M$-4.0M$1.0M
Free Cash Flow$-14.0M$-16.0M$-22.0M$-15.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.11
FCF Yield-96.19%
Quick Ratio2.11
Interest Coverage-9.72
Return 1Y-96.97%
Return 3Y-99.55%
Return 5Y-99.87%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
ENSCEnsysce Biosciences, Inc. $0.46 +6.66% -0.16 $7.04M 0.00%
KALAKALA BIO, Inc. $0.30 -17.61% -0.01 $5.74M 0.00%
KTTAPasithea Therapeutics Corp. $0.44 -0.56% -0.19 $14.73M 0.00%
OGENOragenics Inc. $0.47 +2.29% -0.14 $2.14M 0.00%

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is led by CEO Thomas K. Equels, employs 21 people, headquartered in US, publicly traded since 1995.

AIM ImmunoTech Inc. (AIM) stock trades at $0.18 with a market capitalization of $7.04M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.42, price-to-sales of 78.36. Over the past 52 weeks the stock has ranged between $0.17 and $2.79, and currently trades 93.6% below its 52-week high.

On profitability, AIM ImmunoTech Inc. generates a return on equity (ROE) of 952.76% — well above the market average, a sign of a high-quality business, return on capital employed of -142.02%, an operating margin of -103.70%, a net profit margin of -141.23%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1172.83 +0.28% JNJ Johnson & Johnson $259.74 +1.27% ABBV AbbVie Inc. $275.95 +1.30% MRK Merck & Company, Inc. Common Stock (new) $145.34 +2.08% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.24 +1.43% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.31 +0.97% AMGN Amgen Inc. $411.86 +1.08% GILD Gilead Sciences, Inc. $150.34 +2.21% ABT Abbott Laboratories $99.69 +1.21% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides